|
(Health-NewsWire.Net, June 21, 2015 ) Global Markets Direct's, ‘Guillain-Barre Syndrome - Pipeline Review, H1 2015', provides an overview of the Guillain-Barre Syndrome's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Guillain-Barre Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Guillain-Barre Syndrome and special features on late-stage and discontinued projects.
Inquire more about this Report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=392694 . (This is a premium report price at US$2000 for a single user PDF license)
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope:
• The report provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Guillain-Barre Syndrome and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Guillain-Barre Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Guillain-Barre Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
Inquire for discount on this report http://www.rnrmarketresearch.com/contacts/discount?rname=392694 . (This is a premium report price at US$2000 for a single user PDF license)
Reasons to Buy:
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Guillain-Barre Syndrome
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Guillain-Barre Syndrome pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
More reports on Therapeutics at:
Investigation Report on China Recombinant Factor VIII Market, 2010-2019
Hemophilia is a hereditary bleeding disorder caused by a lack of clotting factor VIII or IX, though not rare, which affects mostly males. Hemophilia A (clotting factor VIII deficiency) is the most common form of the disorder. The number of the cases of hemophilia is about over 0.4 million around the world while that in China is about 0.06-0.1 million, among which 80% lack clotting factor VIII while over half are in severe conditions.
Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor VIII (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor VIII too.
Complete report is available at http://www.rnrmarketresearch.com/investigation-report-on-china-recombinant-factor-market-2010-2019-market-report.html .
RnR Market Research
Ritesh Tiwari
+ 1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
